Used in pharmaceutical research as a potent and selective inhibitor of phosphodiesterase 10A (PDE10A), this compound is investigated for its potential in treating central nervous system disorders, particularly schizophrenia and other psychiatric conditions involving dopamine dysregulation. It modulates intracellular signaling in the striatal pathway by increasing cyclic AMP levels, which may help restore cognitive and behavioral deficits. Due to its blood-brain barrier permeability and favorable pharmacokinetic profile in preclinical models, it serves as a valuable tool compound in neuropharmacology studies and as a lead structure for developing novel antipsychotic agents.